Ikarian Capital, LLC Lyell Immunopharma, Inc. Transaction History
Ikarian Capital, LLC
- $714 Million
- Q1 2025
A detailed history of Ikarian Capital, LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 876,037 shares of LYEL stock, worth $367,935. This represents 0.07% of its overall portfolio holdings.
Number of Shares
876,037
Previous 1,276,037
31.35%
Holding current value
$367,935
Previous $816,000
42.03%
% of portfolio
0.07%
Previous 0.13%
Shares
3 transactions
Others Institutions Holding LYEL
# of Institutions
117Shares Held
175MCall Options Held
2.9KPut Options Held
6K-
Mwg Management Ltd. Washington, DC20.2MShares$8.47 Million18.54% of portfolio
-
Foresite Capital Management Iv, LLC Larkspur, CA16MShares$6.72 Million9.84% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$6.34 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$6.34 Million9.84% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$5.67 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $104M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...